Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases. Its principal products candidates in clinical development include ibrutinib, which is under multiple Phase III studies in hematologic malignancies; a BTK inhibitor lead optimization program targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in phase II clinical trial for the treatment of pancreatic cancer; and a HDAC inhibitor abexinostat, which is in Phase I and II clinical trials for the treatment of solid tumors and hematological malignancies. The company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and other structurally related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; and license agreement with Novo Nordisk A/S to research and develop PCI-27483. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.
Address
999 East Arques Avenue
SUNNYVALE, CA 94085-4521
United States
SUNNYVALE, CA 94085-4521
United States
Website
http://www.pcyc.comKey stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | 53.53% | - |
| Operating margin | 67.55% | - |
| EBITD margin | - | - |
| Return on average assets | 27.86% | - |
| Return on average equity | 34.30% | - |
| Employees | 224 |
No comments:
Post a Comment